Mass General Brigham Research shared a post on LinkedIn:
“A single injection of a genetically engineered virus may help the immune system break into one of cancer’s toughest strongholds: glioblastoma.
In a new Cell study, researchers from Mass General Brigham and Dana-Farber Cancer Institute showed that an oncolytic herpes simplex virus can recruit cancer-fighting T cells deep into brain tumors – turning an immunologically “cold” tumor hot.
In a phase 1 trial of 41 patients with recurrent disease, the therapy extended survival compared to historical outcomes.
“Our findings could have important implications for a cancer whose standard of care hasn’t changed for 20 years,” said E. Antonio Chiocca from the Mass General Brigham Cancer Institute.
Other articles featuring Mass General Brigham Research on OncoDaily.